摘要： 乙型肝炎病毒(HBV)感染是全球性的公共卫生问题,其中慢性乙型肝炎(CHB)是导致肝硬化和肝细胞癌的主要原因。近年来,随着对HBV生命周期的深入研究,HBV前基因组RNA(HBV-pgRNA)作为HBV复制和转录过程中的关键分子,逐渐受到研究者的关注。本文将详细探讨HBV-pgRNA的结构特性、在慢性乙型肝炎病程中的作用、与疾病进展的关系,以及其在诊断和治疗中的潜在应用价值。
杜雷雷, 贾怡敏, 高晓红. 血清HBV RNA在慢性乙型肝炎诊断、治疗及预后中的价值[J]. 肝脏, 2026, 31(1): 132-135.
| [1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023,41(1) : 3-28. [2] Guo J T, Guo H. Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics[J]. Antiviral Res, 2015,122:91-100. [3] Li J, Hu C, Chen Y, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B[J]. BMC Infect Dis, 2021,21(1):567. [4] Dandri M, Petersen J. cccDNA maintenance in chronic hepatitis B-targeting the matrix of viral replication[J]. Infect Drug Resist, 2020,13:3873-3886. [5] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015,64(12):1972-1984. [6] 丁霞, 廖桂婵, 夏牧晔, 等. 探讨长期核苷(酸)类药物治疗慢性乙型肝炎患者停药后复发的影响因素[J]. 新发传染病电子杂志, 2019,4(1):52-55. [7] Lu F, Wang J, Chen X, et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs[J]. Front Med, 2017,11(4):502-508. [8] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016,65(4):700-710. [9] Jung K S, Park J Y, Chon Y E, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J]. J Gastroenterol, 2016,51(8):830-839. [10] Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol, 2018,68(4):847-849. [11] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J]. PLoS Pathog, 2020,16(10):e1008945. [12] Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5′RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum[J]. J Hepatol, 2020,73(1):40-51. [13] Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients[J]. J Virol, 2018,92(24). [14] Lam A M, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants[J]. Antimicrob Agents Chemother, 2017,61(8):e00680-17. [15] Prakash K, Rydell G E, Larsson S B, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J, 2018,15(1):86. [16] Jansen L, Kootstra N A, van Dort K A, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis, 2016,213(2):224-232. [17] Deng R, Liu S, Shen S, et al. Circulating HBV RNA: from biology to clinical applications[J]. Hepatology, 2022,76(5):1520-1530. [18] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015,61(1):66-76. [19] Brakenhoff S M, de Man R A, Boonstra A, et al. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss[J]. Aliment Pharmacol Ther, 2021,53(2):314-320. [20] 张缈曲, 张琪然, 张寒悦, 等. 一种新型乙型肝炎病毒RNA定量检测方法的临床检测性能评估[J]. 中华传染病杂志, 2020,38(12):782-785. [21] Kojabad A A, Farzanehpour M, Galeh H, et al. Droplet digital PCR of viral DNA/RNA, current progress, challenges, and future perspectives[J]. J Med Virol, 2021,93(7):4182-4197. [22] Limothai U, Chuaypen N, Poovorawan K, et al. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification[J]. J Med Virol, 2020,92(12):3365-3372. [23] Verbist B, Adriaensen E, Keersmaekers V, et al. Analyzing magnetic bead QuantiGene(R) Plex 2.0 gene expression data in high throughput mode using QGprofiler[J]. BMC Bioinformatics, 2019,20(1):378. [24] Liu Y Y, Liang X S. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA[J]. World J Hepatol, 2018,10(9):603-611. [25] Cloherty G, Butler E, Kuhns M. Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection[J]. Clin Liver Dis (Hoboken), 2019,13(3):90-92. [26] Wang Y, Liu Y, Liao H, et al. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients[J]. Int J Med Sci, 2022,19(5):858-866. [27] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017. [28] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals[J]. J Clin Virol, 2018,99-100:71-78. [29] Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy[J]. Antivir Ther, 2019,24(2):105-115. [30] Jia W, Zhu M Q, Qi X, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a[J]. Virol J, 2019,16(1):61. [31] Huang C, Li Q, Xu W, et al. Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection[J]. Discov Med, 2020,29(157):119-128. [32] Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection[J]. J Viral Hepat, 2018,25(9):1038-1047. [33] Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study[J]. Hepatol Int, 2020,14(2):212-224. [34] Farag M S, van Campenhout M, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in hbeag-negative chronic hepatitis B[J]. Clin Infect Dis, 2021,72(2):202-211. [35] Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019,26(12):1481-1488. [36] Xia M, Chi H, Wu Y, et al. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment[J]. Aliment Pharmacol Ther, 2021,54(5):709-714. [37] Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues[J]. J Viral Hepat, 2020,27(3):323-328. [38] Chan H, Chan F, Hui A J, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study[J]. J Viral Hepat, 2019,26(1):126-135. [39] 刘燕娜, 樊蓉, 杨瑞锋, 等. 慢性HBV感染者血清HBV RNA检测及临床应用的专家共识[J]. 中华肝脏病杂志, 2022,30(5): 505-512. [40] Ghany M G, King W C, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America[J]. Hepatology, 2021,74(5):2395-2409. [41] Mak L Y, Cloherty G, Wong D K, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy[J]. Hepatology, 2021,73(6):2167-2179. [42] Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection[J]. BMC Gastroenterol, 2019,19(1):53. [43] Fan R, Peng J, Xie Q, et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B[J]. J Infect Dis, 2020,222(4):611-618. |
| [1] | 施烨娟, 陈香梅. HBV整合的分子模式及其对肝细胞癌发生和预后的影响[J]. 肝脏, 2025, 30(9): 1171-1174. |
| [2] | 李凌洁, 杨明, 吴伟平, 吴亚男, 黄永鹏. 恩替卡韦抗病毒治疗逆转慢性乙型肝炎肝纤维化和早期肝硬化的临床观察[J]. 肝脏, 2025, 30(9): 1215-1218. |
| [3] | 黄素钦, 林城, 郑思彧. 血清CHI3L1、GP73和肝纤四项联合检测对慢性乙型肝炎早期肝纤维化的诊断价值[J]. 肝脏, 2025, 30(9): 1219-1224. |
| [4] | 杨啸天, 张颖, 郑昕. 乙型肝炎病毒相关肝细胞癌复发的空间——免疫研究进展[J]. 肝脏, 2025, 30(8): 1023-1025. |
| [5] | 王杏珍, 刘开颜, 王晓燕. 妊娠期乙型肝炎病毒感染患者孕期药物干预策略对母婴预后及产后肝炎发作的影响[J]. 肝脏, 2025, 30(8): 1046-1050. |
| [6] | 马肖敏, 蒋叶舟, 陈国飞. 血清胰岛素样生长因子结合蛋白-7水平对乙型肝炎肝硬化并发急性肾损伤患者的诊断价值[J]. 肝脏, 2025, 30(8): 1061-1065. |
| [7] | 李锋, 牛娜, 吴英. 剪切波弹性成像与门静脉血流动力学预测乙型肝炎肝硬化患者胃底静脉曲张破裂风险的临床评价[J]. 肝脏, 2025, 30(8): 1071-1075. |
| [8] | 万品凤, 周恕敏, 方群, 李娜. 超声定量评估及GGT/PLT在乙型肝炎肝纤维化中的应用[J]. 肝脏, 2025, 30(8): 1076-1079. |
| [9] | 苗莉, 朱敏敏, 李伟, 王娴. 声脉冲辐射力成像技术测量的肝脏硬度值预测失代偿期乙型肝炎肝硬化患者门静脉高压的价值[J]. 肝脏, 2025, 30(8): 1080-1083. |
| [10] | 葛琦, 殷慧康, 柏玲, 叶黛西. Gd-EOB-DTPA增强MRI及MDCT在乙型肝炎肝硬化合并小肝癌诊断中的应用[J]. 肝脏, 2025, 30(8): 1104-1107. |
| [11] | 刘丁境, 牛日雨, 尹伟, 李成忠. 血小板相关参数评估乙型肝炎病毒相关肝细胞癌发生风险和预后的研究进展[J]. 肝脏, 2025, 30(8): 1165-1168. |
| [12] | 梁群, 付伟. 艾米替诺福韦治疗乙型肝炎肝硬化伴低病毒血症2例及文献复习[J]. 肝脏, 2025, 30(8): 1169-1170. |
| [13] | 蒋素贞, 王竞州, 陈香梅, 鲁凤民. 宿主HBV特异性细胞免疫或是慢性乙型肝炎患者核苷(酸)类药物停药不复发和HBsAg清除的决定因素[J]. 肝脏, 2025, 30(7): 889-892. |
| [14] | 李玉龙, 张欣欣. HBsAg亚病毒颗粒:miRNA递送载体及潜在治疗应用[J]. 肝脏, 2025, 30(7): 897-900. |
| [15] | 代雪枫, 丁体龙, 丁烨莹, 马艳春. 核苷类经治低水平HBsAg阳性代偿期乙型肝炎肝硬化患者联合聚乙二醇干扰素α-2b疗效及安全性分析[J]. 肝脏, 2025, 30(7): 926-929. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
